TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37726656

Group type: EXPERIMENTAL
Intervention: Self-performed dietary sodium restriction (two weeks)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Usual diet (two weeks)
Number of subjects: 15
Study: 37726660

Group type: EXPERIMENTAL
Intervention: Tissue oxygen saturation monitoring using near-infrared spectroscopy
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Baseline-3 SD tissue oxygen saturation threshold
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Baseline-2.5 SD tissue oxygen saturation threshold
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Corrected significance for baseline-3 SD and baseline-2.5 SD
Number of subjects: 99
Study: 37726677

Group type: EXPERIMENTAL
Intervention: High intensity interval training (HIIT) for 11 weeks
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (no change in physical exercise habits)
Number of subjects: 67
Study: 37726689

Group type: EXPERIMENTAL
Intervention: Advanced PRF plus with the recurrent application of C-PRF inside the socket every two weeks for 2 months (four times)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Advanced PRF plus alone
Number of subjects: 20
Study: 37726695

Group type: EXPERIMENTAL
Intervention: Atezolizumab (PD-L1 directed immunotherapy, IV infusion, 1680 mg, every 28 days for one year if tolerated)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Atezolizumab (PD-L1 directed immunotherapy)
Number of subjects: 33
Study: 37726771

Group type: EXPERIMENTAL
Intervention: Education Outside the Classroom (EOtC) intervention: a two-day training course for teachers followed by implementation of EOtC >5 hours weekly over one school year.
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group: 15 schools not receiving the EOtC intervention (waitlist control).
Number of subjects: 54
Study: 37726786

Group type: EXPERIMENTAL
Intervention: Patient-derived tumor organoids (PDTO) cultured in a medium supplemented with growth factors and signal pathway inhibitors.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PDTO response to chemo-ICB (immune checkpoint blocker and chemotherapy).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Feasibility of generating PDTO from TNBC.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Establishment of a living biobank of TNBC PDTO.
Number of subjects: 0
Study: 37726806

Group type: EXPERIMENTAL
Intervention: OncoUrine test for bladder cancer diagnosis; tested 47 samples.
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: OncoUrine test for recurrence diagnosis; tested 93 samples.
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: OncoUrine test predicting recurrence during follow-up.
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Correlation of OncoUrine test result with recurrence free survival (RFS) of NMIBC patients.
Number of subjects: 203
Study: 37726820

Group type: EXPERIMENTAL
Intervention: Encapsulated juice powder concentrate
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Plant-based omega fatty acid supplement
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Both supplements combined
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 112
Study: 37726821

Group type: EXPERIMENTAL
Intervention: BRIDGE (DBT + parenting skills)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: DBT skills training
Number of subjects: 180

Group type: COMPARATOR
Intervention: Services-as-usual
Number of subjects: 180
Study: 37726823

Group type: EXPERIMENTAL
Intervention: Brief Negotiation Interview (BNI) alone
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: BNI plus facilitated initiation of medications for alcohol use disorder (BNI + MAUD)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: BNI + MAUD + initiation of computer-based training for cognitive behavioral therapy (CBT4CBT)
Number of subjects: 450

Group type: COMPARATOR
Intervention: BNI alone, BNI + MAUD, BNI + MAUD + CBT4CBT
Number of subjects: 450
Study: 37726843

Group type: EXPERIMENTAL
Intervention: S. aureus surgical site infections (SSI) identified by semi-automated crossmatching bacteriological and electronic health record data.
Number of subjects: 178902

Group type: EXPERIMENTAL
Intervention: Procedure-specific incidence of S. aureus SSI across all surgical specialties.
Number of subjects: 178902

Group type: EXPERIMENTAL
Intervention: Semi-automated approach to utilize big data in epidemiological studies.
Number of subjects: 178902
Study: 37726848

Group type: EXPERIMENTAL
Intervention: BANG smartphone application (24-week eHealth program)
Number of subjects: 19
Study: 37726883

Group type: EXPERIMENTAL
Intervention: Regression equations based on histology features
Number of subjects: 1679
Study: 37726889

Group type: EXPERIMENTAL
Intervention: Balance Program (telemedicine pain intervention)
Number of subjects: 20
Study: 37727203

Group type: EXPERIMENTAL
Intervention: 12-week home-based lifestyle intervention (nutrition and exercise)
Number of subjects: 20
Study: 37727387

Group type: EXPERIMENTAL
Intervention: Intraoperative slow-release dexamethasone intravitreal implant (Ozurdex)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no dexamethasone implant)
Number of subjects: 0
Study: 37727600

Group type: EXPERIMENTAL
Intervention: Depressive symptoms assessed using the Patient Health Questionnaire-9 (PHQ-9)
Number of subjects: 3795

Group type: EXPERIMENTAL
Intervention: Anxiety assessed using the Generalized Anxiety Disorder 7-item scale
Number of subjects: 3795

Group type: EXPERIMENTAL
Intervention: Loneliness assessed using the UCLA 3-item scale
Number of subjects: 3795

Group type: EXPERIMENTAL
Intervention: Cognition assessed using the Montreal Cognitive Assessment 5-Minute Protocol
Number of subjects: 3795
Study: 37727608

Group type: EXPERIMENTAL
Intervention: BHOMA intervention (intensive clinical training, quality improvement measures, support for commodities procurement, improved community outreach, and district level management support)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control phase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention phase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall study
Number of subjects: 0
Study: 37727636

Group type: EXPERIMENTAL
Intervention: Standard North American-type diet for 4 weeks
Number of subjects: 0
Study: 37728045

Group type: EXPERIMENTAL
Intervention: SoC + remdesivir
Number of subjects: 664

Group type: COMPARATOR
Intervention: SoC
Number of subjects: 664
Study: 37728115

Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICIs) combined with tyrosine kinase inhibitors (TKIs)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Low psoas muscle index (PMI) (≤5.5409 cm)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Prognostic nutritional index (PNI)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Geriatric nutritional risk index (GNRI)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Albumin (ALB)
Number of subjects: 124
Study: 37728142

Group type: EXPERIMENTAL
Intervention: Digital self-help plus treatment as usual (TAU)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) only
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Digital self-help plus TAU
Number of subjects: 152
Study: 37728224

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone furoate 50 μg once daily (QD)
Number of subjects: 477

Group type: COMPARATOR
Intervention: Placebo QD
Number of subjects: 477
Study: 37728392

Group type: EXPERIMENTAL
Intervention: Breast implants
Number of subjects: 4639

Group type: EXPERIMENTAL
Intervention: Public mammography screening programme
Number of subjects: 4639
Study: 37728406

Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA) therapy
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Low body weight
Number of subjects: 494

Group type: COMPARATOR
Intervention: Control group (children without epilepsy)
Number of subjects: 494
Study: 37728492

Group type: EXPERIMENTAL
Intervention: 3D image-guided robotic-assisted partial nephrectomy (3D-IGRAPN)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Thermal ablation (TA)
Number of subjects: 198
Study: 37728493

Group type: EXPERIMENTAL
Intervention: SPARE Nephrometry Score
Number of subjects: 1171

Group type: COMPARATOR
Intervention: RENAL Nephrometry Score
Number of subjects: 1171

Group type: COMPARATOR
Intervention: PADUA Nephrometry Score
Number of subjects: 1171

Group type: COMPARATOR
Intervention: Tumor Size
Number of subjects: 1171
Study: 37728696

Group type: EXPERIMENTAL
Intervention: Conservative treatment (including MPFF, diosmin, compression stockings, creams)
Number of subjects: 6084

Group type: EXPERIMENTAL
Intervention: MPFF
Number of subjects: 6084

Group type: EXPERIMENTAL
Intervention: All treatments (including MPFF)
Number of subjects: 6084
Study: 37728787

Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg) in the morning (8.00-10.00 h)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo in the morning (8.00-10.00 h)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg) in the evening (17.00-19.00 h)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo in the evening (17.00-19.00 h)
Number of subjects: 14
Study: 37728803

Group type: EXPERIMENTAL
Intervention: Sulforaphane (SFN) at a daily dose of 90 mg for 24 weeks
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Sulforaphane (SFN)
Number of subjects: 45
Study: 37728907

Group type: EXPERIMENTAL
Intervention: Mirabegron (50 mg/d)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 296
Study: 37728917

Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (ENA) on admission, day 3, and day 5
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Cholecystokinin (CCK)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Leptin
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Glucagon
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Intestinal fatty acid-binding protein 2 (I-FABP2)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Citrulline
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: CCK, leptin, glucagon, I-FABP2, and citrulline
Number of subjects: 172
Study: 37728977

Group type: EXPERIMENTAL
Intervention: FHIR-enabled digital PHR app
Number of subjects: 40
Study: 37728978

Group type: EXPERIMENTAL
Intervention: Thorough Epigenetic Marker Integration Solution (THEMIS) model using cfDNA features (methylated fragment ratio, chromosomal aneuploidy, fragment size index, fragment end motif).
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Combination of THEMIS model with serological indicators (pepsinogen, gastrin-17, Helicobacter pylori).
Number of subjects: 360

Group type: COMPARATOR
Intervention: Standard-of-care screening.
Number of subjects: 360
Study: 37729024

Group type: EXPERIMENTAL
Intervention: Meal sugar-protein balance
Number of subjects: 0
Study: 37729033

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37729076

Group type: EXPERIMENTAL
Intervention: Sargramostim
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 37729078

Group type: EXPERIMENTAL
Intervention: Nonpneumatic Active Compression Device
Number of subjects: 0
Study: 37729132

Group type: EXPERIMENTAL
Intervention: Acupuncture (10 sessions of treatment)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (10 sessions of treatment)
Number of subjects: 60
Study: 37729184

Group type: EXPERIMENTAL
Intervention: KW-0761 (mogamulizumab)
Number of subjects: 49
Study: 37729260

Group type: EXPERIMENTAL
Intervention: EASEL Approach (universal educator-delivered practices)
Number of subjects: 16
Study: 37729613

Group type: EXPERIMENTAL
Intervention: HCL/HCLv patients with COVID-19
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Patients without positive tests
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Patients who tested positive for COVID-19
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Patients with low normal B cells after recent treatment
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Overall cohort of patients with HCL/HCLv
Number of subjects: 503
Study: 37729663

Group type: COMPARATOR
Intervention: Naltrexone 50 mg/day for 8 weeks
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Venlafaxine 225 mg/day for 8 weeks
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Psychiatric comorbidity
Number of subjects: 95
Study: 37729887

Group type: EXPERIMENTAL
Intervention: Etelcalcetide (ETL)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Alfacalcidol (ALFA)
Number of subjects: 62
Study: 37729939

Group type: EXPERIMENTAL
Intervention: Caloric restriction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermittent fasting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supplementation with curcumin, ginkgolide B, saponins, vitamin E, niacinamide, or triptolide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: β-hydroxybutyrate supplements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Personalized dietary guidelines
Number of subjects: 0
Study: 37730089

Group type: EXPERIMENTAL
Intervention: Lanadelumab 150 mg every 4 weeks (Q4W) for patients aged 2 to <6 years
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Lanadelumab 150 mg every 2 weeks (Q2W) for patients aged 6 to <12 years
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Lanadelumab (both Q2W and Q4W regimens)
Number of subjects: 21
Study: 37730193

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 382

Group type: COMPARATOR
Intervention: Moderate Intensity Steady-State (MISS) Training
Number of subjects: 382

Group type: COMPARATOR
Intervention: HIIT vs MISS
Number of subjects: 382
Study: 37730196

Group type: EXPERIMENTAL
Intervention: Benzodiazepine taper with cognitive behavioral therapy (BZT + CBT)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Benzodiazepine taper with health education program (BZT + HE)
Number of subjects: 54
Study: 37730197

Group type: EXPERIMENTAL
Intervention: Five highly disseminable and sustainable cessation components in a factorial experiment
Number of subjects: 0
Study: 37730199

Group type: EXPERIMENTAL
Intervention: Individually tailored exercise prescription (aerobic and strengthening components) supervised remotely by fitness professionals over 20 weeks
Number of subjects: 160

Group type: COMPARATOR
Intervention: Attention control group (details not specified)
Number of subjects: 160
Study: 37730252

Group type: EXPERIMENTAL
Intervention: Preoperative evaluation of endothelial viability using trypan blue staining and custom image analysis
Number of subjects: 0
Study: 37730386

Group type: EXPERIMENTAL
Intervention: Transcutaneous auricular vagus nerve stimulation (taVNS) for 7 days, twice daily for 30 minutes
Number of subjects: 116

Group type: COMPARATOR
Intervention: Sham stimulation for 7 days, twice daily for 30 minutes
Number of subjects: 116
Study: 37730392

Group type: EXPERIMENTAL
Intervention: Smartphone application-based rehabilitation for 12 weeks
Number of subjects: 162

Group type: COMPARATOR
Intervention: Usual outpatient medical treatment without rehabilitation
Number of subjects: 162
Study: 37730397

Group type: EXPERIMENTAL
Intervention: Clinical Decision Aids (CDAs) including those that use procalcitonin testing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard emergency clinical care
Number of subjects: 0
Study: 37730403

Group type: EXPERIMENTAL
Intervention: Torque Teno Virus (TTV) levels measured using the TTV R-GENE kit
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: TTV levels
Number of subjects: 172
Study: 37730405

Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy (aPDT) with erythrosine and blue light (LED)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional treatment (control group)
Number of subjects: 30
Study: 37730415

Group type: EXPERIMENTAL
Intervention: Last Menstrual Period (LMP)
Number of subjects: 42803

Group type: COMPARATOR
Intervention: Ultrasonography (USG)
Number of subjects: 42803
Study: 37730501

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 15 mg/wk for 24 weeks
Number of subjects: 12
Study: 37730530

Group type: EXPERIMENTAL
Intervention: Intradialytic exercise (60 min during the second hour of thrice weekly dialysis for 6 months)
Number of subjects: 44

Group type: COMPARATOR
Intervention: No intradialytic exercise
Number of subjects: 44
Study: 37730561

Group type: EXPERIMENTAL
Intervention: Systematic intervention procedure involving collaboration between GPs, RCs, and employers
Number of subjects: 112

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 112
Study: 37730613

Group type: EXPERIMENTAL
Intervention: Chamomile tea (3 tea bags × 3 times daily)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Chamomile extract capsule (3 times daily)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo capsule (3 times daily)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Chamomile tea
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Chamomile extract capsule
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 12
Study: 37730614

Group type: EXPERIMENTAL
Intervention: Sirtuin1 (SIRT1)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Nicotinamide phosphoribosyl transferase (NAMPT)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: SIRT1
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: NAMPT
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: SIRT1 and NAMPT
Number of subjects: 52
Study: 37730674

Group type: EXPERIMENTAL
Intervention: Post-transcriptional gene silencing of BCL11A expression (gene therapy)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Hydroxyurea (HU)
Number of subjects: 9
Study: 37730689

Group type: EXPERIMENTAL
Intervention: Exercise intervention group
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 95
Study: 37730732

Group type: EXPERIMENTAL
Intervention: 5-Aminovaleric acid betaine (5-AVAB) serum levels
Number of subjects: 143
Study: 37730833

Group type: EXPERIMENTAL
Intervention: HPMC-based nasal spray solution containing human IgG1 antibodies against SARS-CoV-2
Number of subjects: 0
Study: 37730963

Group type: EXPERIMENTAL
Intervention: Group psychotherapy (8 sessions)
Number of subjects: 100
Study: 37730990

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of the subcallosal cingulate (SCC)
Number of subjects: 0
Study: 37731023

Group type: EXPERIMENTAL
Intervention: Nofazinlimab monotherapy (200 mg Q3W)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Regorafenib plus nofazinlimab (400 mg Q6W and 200 mg Q3W)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Regorafenib plus nofazinlimab (part 2a)
Number of subjects: 122
Study: 37731086

Group type: EXPERIMENTAL
Intervention: Spesolimab 3000 mg to W4 then 600 mg q4w
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Spesolimab 3000 mg to W4 then 300 mg q4w
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Spesolimab 1500 mg to W4 then 600 mg q4w
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Spesolimab 1500 mg to W4, 300 mg q4w to W16 then 300 mg q8w
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo switching to spesolimab 600 mg q4w at W16
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Combined spesolimab groups
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo switch to spesolimab
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Spesolimab in non-Asian patients
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Spesolimab and placebo
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Spesolimab
Number of subjects: 152
Study: 37731137

Group type: EXPERIMENTAL
Intervention: Automated telephone call reminder
Number of subjects: 2658

Group type: EXPERIMENTAL
Intervention: Automated text message reminder
Number of subjects: 2658

Group type: COMPARATOR
Intervention: Control (no reminder)
Number of subjects: 2658
Study: 37731394

Group type: EXPERIMENTAL
Intervention: Maternal lipid and metabolic markers (including HDL, triglycerides, glucose)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Maternal lipid and metabolic markers
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Pre-pregnancy BMI and maternal age
Number of subjects: 71
Study: 37731489

Group type: EXPERIMENTAL
Intervention: Dostarlimab plus carboplatin-paclitaxel (DOS-CP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus carboplatin-paclitaxel (PLB-CP)
Number of subjects: 0
Study: 37731491

Group type: EXPERIMENTAL
Intervention: C5 inhibitor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 37731526

Group type: EXPERIMENTAL
Intervention: Procollagen type 1 N-terminal Propeptide (P1NP) quartiles
Number of subjects: 813
Study: 37731529

Group type: EXPERIMENTAL
Intervention: SVT-triggered CS patients
Number of subjects: 769

Group type: COMPARATOR
Intervention: Non-SVT-triggered CS patients
Number of subjects: 769
Study: 37731709

Group type: EXPERIMENTAL
Intervention: Virtual Reality combined with standard physiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard physiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Virtual Reality intervention
Number of subjects: 0
Study: 37731785

Group type: EXPERIMENTAL
Intervention: Standard care plus enhanced community doula support
Number of subjects: 367

Group type: COMPARATOR
Intervention: Standard maternity care
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Enhanced community doula support
Number of subjects: 367
Study: 37731938

Group type: COMPARATOR
Intervention: BBBIP-CorV
Number of subjects: 1351

Group type: EXPERIMENTAL
Intervention: SCTV01C
Number of subjects: 1351

Group type: EXPERIMENTAL
Intervention: SCTV01E
Number of subjects: 1351
Study: 37732075

Group type: EXPERIMENTAL
Intervention: Mom Power intervention (10 group sessions and 3 individual sessions)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group (psychoeducational mailings)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Mom Power intervention
Number of subjects: 122
Study: 37732080

Group type: EXPERIMENTAL
Intervention: Modafinil (100 to 200 mg/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 37732489

Group type: EXPERIMENTAL
Intervention: Individualized blood pressure management strategy targeting intraprocedural SBP to preinterventional baseline values.
Number of subjects: 250

Group type: COMPARATOR
Intervention: Standardized blood pressure management aiming to maintain intraprocedural SBP between 140 and 180 mm Hg.
Number of subjects: 250
Study: 37732496

Group type: EXPERIMENTAL
Intervention: LULs >20 mm
Number of subjects: 1073

Group type: EXPERIMENTAL
Intervention: LULs 16-20 mm
Number of subjects: 1073

Group type: COMPARATOR
Intervention: Baseline screening and follow-up
Number of subjects: 1073